US · YDES
YD Bio Limited Ordinary Shares
- Sector
- Healthcare · Biotechnology
- Headquarters
- Taipei 115001
- Website
- ydesgroup.com
Price · as of 2024-12-31
$4.80
Market cap 605.07M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates YD Bio Limited Ordinary Shares's (YDES) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $4.80
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| YDES | YD Bio Limited Ordinary S… | $4.80 | 605.07M | — | — | — | — | — | — | — | — | — | — | 30.44% | -286.45% | -276.58% | -42.69% | -84.41% | -39.29% | 0.00 | -1893.69 | 13.18 | 12.91 | 2.43 | -28010000.00% | 4576.00% | 838627.00% | — | -6.98 | -274.13% | — | 0.00% | — | — | — | — | — |
| BTX | BlackRock Technology and … | $6.57 | 766.79M | +241% | — | — | — | 35.90 | 0.72 | 31.50 | — | — | 0.72 | 100.00% | 87.75% | 87.75% | 1.87% | 1.87% | 1.84% | 0.00 | 2313.25 | — | — | — | -8265.00% | -8113.00% | 2800.00% | 21.63% | — | 14.55% | 14.41% | 517.40% | 21.63% | 35.90 | 4.62 | 31.50 | 31.17 |
| DAWN | Day One Biopharmaceutical… | $10.60 | 1.09B | +166% | +52,842% | — | — | -9.99 | 2.43 | 6.78 | -5.99 | -509.45 | 2.53 | 89.12% | -80.76% | -67.85% | -22.74% | 1066.44% | -19.68% | 0.01 | — | 8.02 | 7.73 | 1.84 | 196.00% | 2060.00% | 2964.00% | -9.71% | -1.71 | 884.82% | 0.00% | 0.00% | 6.71% | -4.96 | -6.09 | 4.01 | 8.31 |
| GERN | Geron Corporation | $1.68 | 1.07B | +294,119% | -54% | — | — | -6.40 | 3.99 | 14.52 | -5.38 | — | 3.99 | 98.37% | -225.64% | -226.73% | -66.09% | 7931.16% | -35.34% | 0.43 | -9.39 | 5.56 | 5.04 | -0.28 | -1562.00% | 3238692.00% | 3009.00% | -19.62% | -2.48 | 10011.32% | 0.00% | 0.00% | 0.00% | -4.79 | -3.80 | 10.82 | -2.06 |
| GLUE | Monte Rosa Therapeutics, … | $17.75 | 1.16B | — | -72% | — | — | -6.50 | 2.12 | 6.25 | -1.96 | — | 2.12 | 89.26% | -107.26% | -96.14% | -36.15% | 142.78% | -19.58% | 0.19 | — | 2.40 | 2.37 | 2.49 | -6274.00% | — | -16048.00% | 8.05% | 0.27 | -66.90% | 0.00% | 0.00% | 21.20% | -1.76 | 3.76 | 1.89 | 0.08 |
| LENZ | LENZ Therapeutics, Inc. | $13.49 | 422.1M | — | — | — | — | -10.13 | 2.47 | — | -5.96 | — | 2.47 | 0.00% | — | — | -89.37% | 72.47% | -34.84% | 0.01 | — | 20.36 | 20.09 | 0.38 | -8471.00% | — | -91.00% | -11.88% | -5.71 | 74.02% | 0.00% | 0.00% | 0.00% | -5.06 | -4.95 | — | 26.23 |
| MRVI | Maravai LifeSciences Hold… | $3.56 | 516.14M | +2,414% | -55% | — | +382% | -2.27 | 2.47 | 2.82 | -4.45 | — | -7.64 | 18.30% | -69.20% | -70.41% | -85.84% | -61.48% | -25.95% | 0.17 | -4.79 | 6.60 | 5.40 | 2.35 | -1429.00% | -2834.00% | 21867.00% | -13.50% | -1.28 | -34.44% | 0.00% | 0.00% | 44.99% | -2.66 | -4.84 | 1.84 | 0.89 |
| PRME | Prime Medicine, Inc. | $4.62 | 833.96M | — | -79% | — | — | -1.45 | 1.86 | 95.42 | -0.69 | — | 1.86 | 100.00% | -6787.36% | -6566.61% | -136.88% | -1418.83% | -79.73% | 0.27 | — | 5.58 | 5.02 | 0.72 | -2417.00% | — | -2525.00% | -45.73% | -3.24 | -912.12% | 0.00% | 0.00% | 39.96% | -0.67 | -1.04 | 45.25 | -3.59 |
| TBPH | Theravance Biopharma, Inc… | $18.25 | 924.77M | +61% | -73% | — | — | -8.25 | 2.65 | 7.23 | -11.10 | -55.01 | 2.65 | 100.00% | -72.92% | -87.63% | -29.04% | -31.64% | -15.33% | 0.28 | -18.44 | 5.02 | 4.89 | -0.31 | 1500.00% | 1212.00% | -5975.00% | -2.55% | -0.36 | -8.00% | 0.00% | 0.00% | 0.67% | -9.09 | -35.98 | 6.63 | -2.07 |
| TYRA | Tyra Biosciences, Inc. | $33.31 | 1.78B | — | — | — | — | -7.24 | 1.82 | — | -2.80 | — | 1.82 | 0.00% | — | — | -31.60% | -1368.86% | -29.34% | 0.02 | — | 23.81 | 23.53 | 0.83 | -679.00% | — | 3836.00% | -11.25% | -4.78 | -925.54% | 0.00% | 0.00% | 5.54% | -2.79 | -4.13 | — | 17.59 |
| VIR | Vir Biotechnology, Inc. | $9.09 | 1.26B | +144% | -52% | — | — | -2.95 | 1.69 | 18.87 | -2.39 | — | 1.75 | 82.92% | -682.68% | -638.87% | -45.73% | -112.47% | -36.47% | 0.24 | — | 5.54 | 5.03 | 0.11 | -1749.00% | -761.00% | -1257.00% | -30.66% | -4.22 | -95.31% | 0.00% | 0.00% | 0.00% | -2.17 | -2.57 | 14.85 | 0.63 |
About YD Bio Limited Ordinary Shares
Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases with unmet medical need. The company is based in Taipei, Taiwan.
- CEO
- Ethan Shen
- Employees
- 4
- Beta
- 0.11
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $4.80) − 1 = — (DCF, example).